Brian Frenzel has over 30 years of experience managing and advising companies in the medical products arena. Currently, Brian Frenzel serves as a Director of SanBio, Inc., a company developing regenerative therapies for neurodegenerative diseases. The Company’s lead product is SB623, which is derived from donor bone marrow cells.
SanBio researchers issued a report in April 2014 stating that they had successfully injected SB623 cells into the brains of 18 patients who suffered disability due to ischemic cerebral strokes. All 18 patients exhibited signs of improvement, and several showed dramatic improvement. The authors of the study reported no adverse reactions due to the procedure.
SB623 cells have also proven effective in recovering neurological function in animal models of traumatic brain injury (TBI) and Parkinson’s disease.